Structure Therapeutics price target lowered to $86 from $91 at JMP Securities

JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Structure Therapeutics to $86 from $91 and keeps an Outperform rating on the shares. Structure Therapeutics remains on track to start the Phase 2b obesity trial for its small molecule GLP-1R agonist, GSBR-1290, in Q4, the analyst tells investors in a research note. The firm likes that 12-week weight loss data for the oral GLP-1R agonist GSBR-1290 is on par with first-in-class orforglipron in obese, non-diabetics, and and thinks both tolerability and weight loss will improve in the Phase 2b trial.